Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Stock Information for Indaptus Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Indaptus Therapeutics Inc.

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics Provides Clinical Update
Indaptus Therapeutics to Present at the H.C. Wainwright 27?? Annual Global Investment Conference
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics Announces Reverse Stock Split
Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.